NICE guidance recommends tirzepatide at a BMI 35 kg/m 2 with one weight-related co-morbidity, but the NHS in England is not likely to meet that goal for another 12 years, with a much more restrictive initial criteria of a BMI 40 kg/m 2 and four out of a list of five co-morbidities
Retatrutide may help preserve lean mass during weight loss, but some muscle loss can still occur
The real question isn't whether compounded tirzepatide works, but whether its tradeoffs in consistency, safety, and predictability are acceptable for long-term use
The hidden cost is weeks of fragmented attempts and appointments that start with, "I think it happens when..." rather than with usable data
How is works: GLP-1 receptor: satiety signalling and slower gastric emptying GIP receptor: post-prandial insulin response and fat metabolism Practical logistics so your work isnt waiting on a parcel Glucagon receptor: promotes energy expenditure and fat mobilisation The combined pathway engagement is being investigated for additive or synergistic effects across these systems
